Spark Therapeutics, the gene therapy division that Roche purchased for $4.3 billion in 2019, has undergone a significant reorganisation.

Lenacapavir from Gilead Sciences has shown promise when dosed even more widely apart - only once a year...

JnJ, Legend expanding cell therapy capacity.

For ten titans of industry in 2025, the U.S. patent runway is coming to a close.

This month we've been watching how different companies are managing their pipelines, and keeping Eyes On other hot news topics.

Here at PharmaTell, we have Eyes on FDA Approvals for 2025. Below, we share the monthly Novel Drug and Biologic License Application Approval

We've had Eye's On the JP Morgan Healthcare Conference, Lifesciences 2024 restructuring stats, and some new drug development partnerships.

According to an annual PwC study released in December, the amount of M&A activity in the pharmaceutical and life sciences sectors in 2024...

Check out the final listings of FDA NDA and BLA approvals for 2024.

We've highlighted a few firms: Lilly, AbbVie, Pfizer, Novo Nordisk, BMS, Roche, Novartis, Merck, AstraZeneca, GSK, Viatris, Teva, and Amgen.

This week, we had eyes on data readouts, launch metrics, M&A, and more. Catch up with the news from Roche, AstraZeneca, Lundbeck, and AbbVie

We've had Eyes On some of the recent deals, results, and investor actions. Check out the happenings at Sanofi/Opella, Pfizer, Regeneron, and

Last month, we had Eyes On some of the latest approvals, M&A and litigation. Read more about AbbVie, Genentech, Lundbeck, and GSK ...

Eye's on the Amgen data releases for gMG & Atopic Dermatitis, the BMS approval of Cobenfy for schizophrenia, and Pfizer's Oxbryta recall...

This month, we've had Eyes on investment trends, strategic restructuring, and FDA decisions. Fall seems to be gearing up, and we can't wait

We've had our Eyes On some of the latest Pharmaceutical news including approvals, partnering, mergers, research programs, and

his week we've been looking at the competition heating up due to a combination of M&A, biosimilar entrants, and new clinical data ...

The ASCO 2024 annual meeting took place from 31st May to 4th June. A number of firms presented data, and others used this as an opportunity

Check out this Top Drugs of 2023 list with links to interesting reports in PharmaTell Studio. Contact us for a trial.

This week we've had eyes on BioPharma happenings plus a 2023 Top Selling Drugs list.